Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.

What are you looking for?

Commercialization
CNS/Neuroscience

Psychedelic Development at an Inflection Point: From Broad Promise to True Segmentation

In this video, Kristofor Peterson, BSN, RN, Vice President of Full Service Commercial Solutions, examines the current psychedelic drug development landscape and shares key considerations for sponsors advancing mid- and late-stage assets toward regulatory approval and commercial success.

Move your psychedelic program forward with a partner that understands the path from clinical development to commercial success.

Learn More

Interested in Syneos Health®?

Get in touch

Syneos Health Advances AI-Powered Clinical Ecosystem to Optimize Trial Performance and Speed Decision-Making

Psychedelic Development at an Inflection Point: From Broad Promise to True Segmentation

From Static FSP to Operating Models That Keep Pace With Change

Everybody Wins: Elevating the Patient Voice

Early Signals at ASCO 2026 | Can TIL Therapy Reach More Patients?

Redefining Value in Obesity Drug Development: A Focus on the Full Cardiometabolic Continuum

Healthcare AIX 2026: Transforming Productivity Structures in the Era of Agentic Workflows

Moving Beyond AI Hype to Measurable Commercial Impact

Offcanvas

What are you looking for?

Psychedelic Development at an Inflection Point: From Broad Promise to True Segmentation

Move your psychedelic program forward with a partner that understands the path from clinical development to commercial success.

Offcanvas

What are you looking for?

Psychedelic Development at an Inflection Point: From Broad Promise to True Segmentation

Move your psychedelic program forward with a partner that understands the path from clinical development to commercial success.

Related Content